Oclassen Pharmaceuticals Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $135M

Oclassen Pharmaceuticals General Information

Description

Developer of therapeutics in the fields of dermatology and sexually transmitted diseases. The company offers dermatology-related pharmaceutical products for the prevention, diagnosis, and treatment of skin diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Pelican Way
  • San Rafael, CA 94901
  • United States
Primary Industry
Pharmaceuticals
Acquirer
Corporate Office
  • 100 Pelican Way
  • San Rafael, CA 94901
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oclassen Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 27-Feb-1997 $135M Completed Generating Revenue
5. IPO 27-Mar-1992 Cancelled Generating Revenue
4. Later Stage VC 01-Jan-1990 Completed Generating Revenue
3. Early Stage VC 20-Mar-1989 Completed Product Development
2. Early Stage VC (Series B) 03-Sep-1987 $3.25M $4.25M Completed Generating Revenue
1. Seed Round 01-Apr-1986 $1M $1M Completed Startup
To view Oclassen Pharmaceuticals’s complete valuation and funding history, request access »

Oclassen Pharmaceuticals Patents

Oclassen Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-6040298-A Administering 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-iodouracil, 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-iodocytosine Inactive 23-Dec-1992
AU-5960794-A Compositions effective against acyclovir-resistant strains of herpes viruses Inactive 23-Dec-1992
WO-1994014457-A1 Compositions effective against acyclovir-resistant strains of herpes viruses Inactive 23-Dec-1992
JP-H069403-A Composition for medical treatment of infection and disease caused by b-type hepatitis virus (hbv) Inactive 06-Apr-1992
EP-0565412-A1 Compositions containing 5-iodouracil derivatives for the treatment of hepatitis b infections Inactive 06-Apr-1992 A61K31/70
To view Oclassen Pharmaceuticals’s complete patent history, request access »

Oclassen Pharmaceuticals Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
3i Group PE/Buyout Minority
Bessemer Venture Partners Venture Capital Minority
Burr, Egan, Deleage Venture Capital Minority
Fairfield Ventures Venture Capital Minority
Horn Ventures Partners Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Oclassen Pharmaceuticals FAQs

  • Where is Oclassen Pharmaceuticals headquartered?

    Oclassen Pharmaceuticals is headquartered in San Rafael, CA.

  • What industry is Oclassen Pharmaceuticals in?

    Oclassen Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Oclassen Pharmaceuticals a private or public company?

    Oclassen Pharmaceuticals is a Private company.

  • What is the current valuation of Oclassen Pharmaceuticals?

    The current valuation of Oclassen Pharmaceuticals is .

  • What is Oclassen Pharmaceuticals’s current revenue?

    The current revenue for Oclassen Pharmaceuticals is .

  • How much funding has Oclassen Pharmaceuticals raised over time?

    Oclassen Pharmaceuticals has raised $5.25M.

  • Who are Oclassen Pharmaceuticals’s investors?

    3i Group, Bessemer Venture Partners, Burr, Egan, Deleage, Fairfield Ventures, and Horn Ventures Partners are 5 of 7 investors who have invested in Oclassen Pharmaceuticals.

  • When was Oclassen Pharmaceuticals acquired?

    Oclassen Pharmaceuticals was acquired on 27-Feb-1997.

  • Who acquired Oclassen Pharmaceuticals?

    Oclassen Pharmaceuticals was acquired by Allergan.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process